市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Erasca, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.4
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.5 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.38 |
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 11.69% |
| 机构持股比例 | 84.38% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 31 Mar 2026 | 24,675,188 |
| Venrock Adviser, Llc | 31 Mar 2026 | 16,382,812 |
| Vivo Capital, Llc | 31 Mar 2026 | 12,151,480 |
| Siren, L.L.C. | 31 Mar 2026 | 11,244,246 |
| Arch Venture Management, Llc | 31 Mar 2026 | 7,091,557 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合